NASH Resolution and Fibrosis Improvement Study at Week 52

The New England Journal of Medicine was established in ______

Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver ______

The phase 3 trial involves adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 ______ to F4 [cirrhosis])

Patients were randomly assigned in a 1:1:1 ratio to receive once-daily resmetirom at a dose of 80 mg or 100 mg or ______

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved ______

NASH resolution includes a reduction in the nonalcoholic fatty liver disease [NAFLD] activity score by ≥2 points, with higher scores indicating more severe ______

The primary analysis population consisted of 966 patients (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the ______ group)

NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group, 29.9% in the 100-mg resmetirom group, compared to 9.7% in the ______ group

The two primary end points at week 52 were NASH resolution with no worsening of fibrosis and an improvement in fibrosis by at least one stage with no worsening of the NAFLD activity ______

Overall, 966 patients formed the primary analysis population with 322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the ______ group